Paracetamol

Alnylam Announces U.S. Food and Drug Administration (FDA) Acceptance of Supplemental New Drug Application for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

Retrieved on: 
星期二, 二月 21, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, RDA, Periodic breathing, Headache, PDUFA, Patisiran, Nyctalopia, Quality of life, Premedication, Polyneuropathy, Patient, Back pain, ISA, ATTR, IRR, Disease, Agency, Risk, Abdominal pain, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Paracetamol, Heart failure, Therapy, Nausea, New Drug Application, Shanda, Serum, Cardiomyopathy, Vitamin A deficiency, Vitamin A, Medication, Prescription Drug User Fee Act, International Symposium on Endovascular Therapy, APOLLO, Food, RNA interference, Pharmaceutical industry, Dietary supplement, Amyloidosis

The FDA has set an action date of October 8, 2023 under the Prescription Drug User Fee Act (PDUFA).

Key Points: 
  • The FDA has set an action date of October 8, 2023 under the Prescription Drug User Fee Act (PDUFA).
  • The Agency also noted that they are planning to hold an advisory committee meeting to discuss the application.
  • Patisiran is the established name for ONPATTRO®, which is currently approved by the U.S. FDA for the treatment of the polyneuropathy of hereditary ATTR amyloidosis in adults.
  • “ATTR amyloidosis with cardiomyopathy is an increasingly recognized cause of heart failure for which there are limited treatment options.

Seqens Group Opens Flagship Pharmaceutical R&D Center in Greater Boston

Retrieved on: 
星期二, 一月 31, 2023
Technology, Research, Chemicals, Plastics, Nanotechnology, Manufacturing, Biotechnology, Health, Pharmaceutical, Science, Biocatalysis, Therapy, Safety, API, Excipient, Lipid, RNA, Paracetamol, R, Multimedia, COVID, Fine chemical

Seqens Group , an integrated leader in the development and manufacture of active pharmaceutical ingredients (APIs) and intermediates, today announced that it has opened Seqens Boston R&D Center, a state-of-the-art, 15,000 square-foot R&D center in Devens, Mass.

Key Points: 
  • Seqens Group , an integrated leader in the development and manufacture of active pharmaceutical ingredients (APIs) and intermediates, today announced that it has opened Seqens Boston R&D Center, a state-of-the-art, 15,000 square-foot R&D center in Devens, Mass.
  • View the full release here: https://www.businesswire.com/news/home/20230131005277/en/
    Seqens Group opens the Seqens Boston R&D Center, a state-of-the-art, 15,000 square-foot R&D center in Devens, Mass.
  • The Seqens Boston R&D Center expands project flow, enhances quality and accelerates development of APIs and excipients, including lipids used for the manufacture of RNA vaccines for COVID.
  • Seqens is also committed to the highest levels of environmental, social and governance standards, with 15 EcoVadis platinum and gold sites among its global integrated network.

China Paracetamol Market Export Analysis 2023-2032: Exports Likely to Continue Growing alongside Demand - ResearchAndMarkets.com

Retrieved on: 
星期二, 一月 24, 2023
Health, Pharmaceutical, Major Players, Research report, Coronavirus, Market, Virus, Medicine, St Dominic, Downham Market, Competitive advantage, Impact of the COVID-19 pandemic, API, Respiratory disease, Paracetamol, Chemistry, China Energy Research Report, Prevalence, COVID-19, Clothing, Rare-earth element

Due to the increase in export unit price, China's paracetamol export value instead rose in 2021 despite the decrease in export volume.

Key Points: 
  • Due to the increase in export unit price, China's paracetamol export value instead rose in 2021 despite the decrease in export volume.
  • Which Companies are the Major Players in China's Paracetamol Export Market and What are their Competitive Benchmarks?
  • What are the Competitive Advantages of the Major Players in China's Paracetamol Export Market?
  • Which Segment of China's Paracetamol Export is Expected to Dominate the Market in 2032?

Acute Pain Market to Observe Growth at a CAGR of 8.3% During the Study Period (2019-2032), Assesses DelveInsight

Retrieved on: 
星期四, 一月 26, 2023
New Drug Application, Ibuprofen, LAS, United Kingdom, Fever, VAS, X-ray, Insomnia, Methoxyflurane, FDA, MRI, Hypoesthesia, Disease, IASP, Pain, Sufentanil, Trauma, Spasm, Paracetamol, Vertex, Patient, Depression, International Association, Medication, Weight loss, NDA, Abdominoplasty, MVP, International Association for the Study of Pain, Pregabalin, CT, Greatest Hits (Throbbing Gristle album), Fatigue, Inflammation, Ketorolac, VRS, Combustion, Chills, POC, Cough, Anxiety, Vertex Pharmaceuticals, TLC, Pharmaceutical industry, Dietary supplement, Poultry farming

LAS VEGAS, Jan. 26, 2023 /PRNewswire/ -- DelveInsight's Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight analysis, the acute pain market size in the US was approximately USD 3 billion in 2021.
  • According to the assessment done by DelveInsight, the estimated total acute pain cases in the US was approximately 100 million in 2021.
  • As per the DelveInsight estimates, in the US, in 2021, diagnosed incident cases of acute pain were approximately 94 million.
  • The acute pain market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Acute Pain Market to Observe Growth at a CAGR of 8.3% During the Study Period (2019-2032), Assesses DelveInsight

Retrieved on: 
星期四, 一月 26, 2023
New Drug Application, Ibuprofen, LAS, United Kingdom, Fever, VAS, X-ray, Insomnia, Methoxyflurane, FDA, MRI, Hypoesthesia, Disease, IASP, Pain, Sufentanil, Trauma, Spasm, Paracetamol, Vertex, Patient, Depression, International Association, Medication, Weight loss, NDA, Abdominoplasty, MVP, International Association for the Study of Pain, Pregabalin, CT, Greatest Hits (Throbbing Gristle album), Fatigue, Inflammation, Ketorolac, VRS, Combustion, Chills, POC, Cough, Anxiety, Vertex Pharmaceuticals, TLC, Pharmaceutical industry, Dietary supplement, Poultry farming

LAS VEGAS, Jan. 26, 2023 /PRNewswire/ -- DelveInsight's Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight analysis, the acute pain market size in the US was approximately USD 3 billion in 2021.
  • According to the assessment done by DelveInsight, the estimated total acute pain cases in the US was approximately 100 million in 2021.
  • As per the DelveInsight estimates, in the US, in 2021, diagnosed incident cases of acute pain were approximately 94 million.
  • The acute pain market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

China Paracetamol Market Export Analysis 2023-2032: Prevalence of Respiratory Diseases Bolsters Growth

Retrieved on: 
星期三, 一月 25, 2023
Market, Respiratory disease, Chemistry, Research report, Major Players, Coronavirus, Medicine, China Energy Research Report, Competitive advantage, COVID-19, Prevalence, API, Paracetamol, Impact of the COVID-19 pandemic, St Dominic, Downham Market, Virus, Clothing, Rare-earth element

China is one of the major paracetamol API producers and exporters in the world, exporting paracetamol in large quantities every year.

Key Points: 
  • China is one of the major paracetamol API producers and exporters in the world, exporting paracetamol in large quantities every year.
  • Due to the increase in export unit price, China's paracetamol export value instead rose in 2021 despite the decrease in export volume.
  • Which Companies are the Major Players in China's Paracetamol Export Market and What are their Competitive Benchmarks?
  • Which Segment of China's Paracetamol Export is Expected to Dominate the Market in 2032?

GeoVax Receives Notice of Allowance for Zika Vaccine Patent

Retrieved on: 
星期三, 一月 25, 2023
Antibody, Disease, Infection, Biotechnology, Rest, Zika virus, COVID-19, Cancer, Guillain–Barré syndrome, Neurodegeneration, Vaccine, Risk, Pregnancy, Dengue fever, Vaccination, Microcephaly, Tick-borne encephalitis, Patient, Patent, GeoVax, NS1, Flavivirus, Paracetamol, MVA, Woman, Yellow fever, ADE, Flaviviridae, ZIKV

ATLANTA, GA, Jan. 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that the U.S. Patent and Trademark Office issued a Notice of Allowance for Patent Application No. 17/000,768 titled, “Method for Generating a ZIKV Immune Response Utilizing a Recombinant Modified Vaccinia Ankara Vector Encoding the NS1 Protein.”

Key Points: 
  • ATLANTA, GA, Jan. 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that the U.S. Patent and Trademark Office issued a Notice of Allowance for Patent Application No.
  • 17/000,768 titled, “Method for Generating a ZIKV Immune Response Utilizing a Recombinant Modified Vaccinia Ankara Vector Encoding the NS1 Protein.”
    “Our novel Zika vaccine candidate, GEO-ZM02, is constructed using our modified vaccinia Ankara (MVA) vector platform.
  • Preclinical studies demonstrated a single dose of GEO-ZM02 provided 100% protection against a lethal dose of Zika virus,” stated GeoVax CEO David Dodd.
  • The claims to be granted in the patent cover GeoVax’s MVA vector comprising a nucleic acid sequence encoding a ZIKV nonstructural (NS1) protein, of which GEO-ZM02 is designed.

EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE IN EUROPE

Retrieved on: 
星期二, 一月 10, 2023
Cerebral edema, Intracerebral hemorrhage, Anticoagulant, Arthralgia, Aspirin, Stroke, MRI, Dizziness, Cerebral contusion, Seizure, Hypotension, Effectiveness, Status epilepticus, Diarrhea, Clopidogrel, Alzheimer's disease, Aneurysm, Risk, Vomiting, ARIA, Chills, AND, Disease, Nausea, Patient, Intracranial hemorrhage, Vascular malformation, Cough, Paracetamol, Hypertension, Focal neurologic signs, Headache, Observation, Incidence, Tissue plasminogen activator, Confusion, Siderosis, Fever, Medical device, Pharmaceutical industry, Medical imaging, Clothing

Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

Key Points: 
  • Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.
  • There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.
  • Depending on ARIA severity, use clinical judgment in considering whether to continue dosing, temporarily discontinue treatment, or permanently discontinue LEQEMBI.
  • In Study 1, 15% of LEQEMBI-treated patients, compared to 6% of placebo-treated patients, stopped study treatment because of an adverse reaction.

Practice Winter Wellness with Tips from Pediatric ENT and Dr. Noze Best Founder

Retrieved on: 
星期三, 一月 4, 2023
Medical Devices, Parenting, Infectious Diseases, Children, Baby, Maternity, Family, Health, Consumer, General Health, Wheeze, Hospital, Late, Degenerative disease, RSV, Child, Congestion, Alertness, COVID-19, Virus, Dehydration, Disease, ENT, Breathe Me, Learning, Mayo Clinic, Nose, Paracetamol, Suction, Parent, Lip, Human, Drinking, Clinical professor, Tears, Ibuprofen, Fever, Toy, Health insurance, Residential care

, esteemed pediatric ENT, and founder and Chief Medical Officer of Dr. Noze Best , shares his advice to help families practice wellness this winter—and year-round.

Key Points: 
  • , esteemed pediatric ENT, and founder and Chief Medical Officer of Dr. Noze Best , shares his advice to help families practice wellness this winter—and year-round.
  • “For infants and young children, respiratory illnesses can become very serious,” says Dr. Goudy.
  • As RSV and flu continue to spread this winter, parents can take steps to avoid hospital visits and keep their families well.
  • For more resources about treating RSV and other respiratory illnesses from Dr. Goudy and his team, visit www.drnozebest.com/blogs/the-doctor-is-in

Insights on the Knee Surgeries and Arthroplasty Pain Management Therapeutics Global Market to 2030 - by Drug, Distribution Channel and Region - ResearchAndMarkets.com

Retrieved on: 
星期三, 十二月 14, 2022
Health, Pharmaceutical, Therapy, OTC, Food, GlaxoSmithKline, Regulation of tobacco by the U.S. Food and Drug Administration, National Center for Spinal Disorders, National Center for Biotechnology Information, Ibuprofen/paracetamol, US, Research, TKA, Ibuprofen, Pain, Nonsteroidal anti-inflammatory drug, Growth, Marketing, Pharmaceutical industry, Dentistry, Paracetamol

The "Global Knee Surgeries and Arthroplasty Pain Management Therapeutics Market - Size, Share, Outlook, and Opportunity Analysis, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Knee Surgeries and Arthroplasty Pain Management Therapeutics Market - Size, Share, Outlook, and Opportunity Analysis, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • Many types of medicines are available to help control pain, including opioids, non-steroidal anti-inflammatory drugs (NSAIDs), Acetaminophen, etc.
  • Medications help people feel more comfortable, allowing one to start moving sooner, get the strength back more quickly, and recover from knee surgeries and arthroplasty faster.
  • Increasing research and development activities by the key players for the development and launch of knee surgeries and arthroplasty pain management drugs are expected to drive the growth of the global knee surgeries and arthroplasty pain management therapeutics market over the forecast period.